Date: 2015-06-01
Type of information: Product launch
Product name: CAP®Go platform
Compound: expression platform
Therapeutic area: Technology - Services
Action mechanism: CAP®Go expression platform is used to express therapeutic glycoproteins with tailor-made or fully human glycosylation patterns for significantly improved physicochemical and pharmacological properties. This expression platform comprises a portfolio of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities and allows for the recombinant production of a variety of complexly glycosylated proteins such as high molecular mass multimeric proteins including plasma proteins, coagulation factors, cytokines and antibodies.
Company: CEVEC Pharmaceuticals (Germany)
Disease:
Latest news: * On June 1, 2015, CEVEC Pharmaceuticals, a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
